19.1.2026
SL Insight Newsletter #15
US wants to enshrine MFN in law
Marcel Boller
On January 15, 2026, the White House outlined its "Great Healthcare Plan" – with a key message to the pharmaceutical industry: MFN deals are to be codified by law and thus stabilized across legislative periods. At the same time, other levers such as TrumpRx and PBM kickbacks are to be firmly anchored.
Impact on Switzerland?
If MFN is codified in the US, pressure will increase to systematically use foreign price anchors, meaning that prices from the specialty list will become a more frequent part of US arguments. This applies in particular to internationally visible price levels such as those in Switzerland, which sends out frequent and noticeable signals through three-year reviews and indication extensions.
